RCEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AVITA Medical Inc (RCEL) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are some positive catalysts such as hedge fund buying and a bullish moving average trend, the company's financial performance is weak, with declining revenue and EPS. Additionally, technical indicators like MACD and RSI do not provide a clear buy signal, and there is no strong momentum in the options data or proprietary trading signals to support an immediate purchase.
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 36.938, not signaling an overbought or oversold condition. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting some upward trend potential. Key support is at 4.595, and resistance is at 5.328.
Hedge funds are significantly increasing their buying activity, with a 534.61% increase over the last quarter. Analysts from Northland have initiated coverage with an Outperform rating and a $10 price target, citing potential for double-digit revenue growth and cash breakeven by FY27.
The company's financial performance is weak, with declining revenue (-4.30% YoY), EPS (-13.64% YoY), and gross margin (-6.97% YoY) in the latest quarter. Insider trading activity is neutral, and there is no recent news or congress trading data to provide additional support.
In Q4 2025, the company's revenue dropped by 4.30% YoY to $17.615 million. Net income improved slightly but remains negative at -$11.621 million. EPS fell by 13.64% YoY to -0.38, and gross margin declined to 81.9%, down 6.97% YoY.
Northland initiated coverage with an Outperform rating and a $10 price target, citing potential for revenue growth and cash breakeven by FY27. However, Lake Street remains cautious with a Hold rating and a price target of $3.50, awaiting further business stabilization.
